Crestline Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Crestline Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-32,439	Closed	-$1.23M	–	242
2022 Q4	$1.23M	Sell	32,439 -4,669	-13%	-$161K	0.18%	88
2022 Q3	$933K	Buy	37,108 +10,400	+39%	+$288K	0.13%	119
2022 Q2	$812K	Buy	26,708 +13,621	+104%	+$406K	0.11%	135
2022 Q1	$429K	Buy	+13,087	New	+$388K	0.05%	192
2021 Q4	–	Sell	-5,909	Closed	-$594K	–	288
2021 Q3	$594K	Sell	5,909 -103	-2%	-$12.1K	0.06%	144
2021 Q2	$851K	Buy	+6,012	New	+$679K	0.07%	107
2018 Q3	–	Sell	-26,439	Closed	-$925K	–	243
2018 Q2	$925K	Sell	26,439 -62,236	-70%	-$1.9M	0.1%	200
2018 Q1	$1.82M	Buy	88,675 +19,769	+29%	+$509K	0.23%	82
2017 Q4	$1.95M	Buy	68,906 +8,442	+14%	+$236K	0.2%	42
2017 Q3	$1.88M	Buy	+60,464	New	+$1.82M	0.26%	71

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's RETA Position: Q1 2023 in Review

Crestline Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 32,439 shares — an estimated $1.23M sold.

Crestline Management first reported a position in RETA in Q3 2017 and held it in 10 quarters. The position peaked at $1.95M in Q4 2017. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Crestline Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Crestline Management sold 32,439 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $1.23M.
Crestline Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 10 quarters.
Crestline Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.95M in Q4 2017.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Crestline Management's 13F filing for Q1 2023, filed 15 May 2023.